16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
Clinical trial NCT02159053 · COMPLETED
Trial details
- NCT number
- NCT02159053
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-18
- Primary completion
- 2016-02-23
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.